ÐÂÎÅÖÐÐÄ
News Center
µÚÊ®¸ö˳Ӧ֢ÉÏÊÐÉêÇë»ñÊÜÀí£¬£¬£¬£¬£¬ £¬£¬°²ÂÞÌæÄΌѪ¹ÜÌìÉúÍŽáÁÆ·¨Ô¶¾°ÁÉÀ«
Ðû²¼Ê±¼ä£º2024-11-22
11ÔÂ21ÈÕ£¬£¬£¬£¬£¬ £¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾£¨1177.HK£©1ÀàÁ¢ÒìÒ©ÑÎËá°²ÂÞÌæÄὺÄÒµÚ10¸ö˳Ӧ֢——ÍŽáÅÉ°²ÆÕÀûµ¥¿¹×¢ÉäÒºÒ»ÏßÖÎÁÆÍíÆÚ¸Îϸ°û°©µÄÉÏÊÐÉêÇë»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©ÊÜÀí¡£¡£¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬£¬ £¬£¬ÑÎËá°²ÂÞÌæÄὺÄÒÒÑ»ñÅúÉÏÊлòÊÜÀíµÄ˳Ӧ֢º¸Ç·Î°©¡¢Èí×éÖ¯ÈâÁö¡¢¼××´ÏÙ°©¡¢Éöϸ°û°©¡¢¸Îϸ°û°©¡¢×Ó¹¬ÄÚĤ°©6´ó°©ÖÖ£¬£¬£¬£¬£¬ £¬£¬Ò»Á¬Õ¹ÏÖÁËÆäÔÚ¿¹Ñª¹ÜÌìÉúÖÎÁÆÁìÓòµÄÁÉÀ«Ó¦ÓÃÔ¶¾°¡£¡£¡£¡£¡£¡£¡£
Ô·¢ÐԸΰ©ÊÇÈ«ÇòµÚÆß´ó³£¼ûµÄ¶ñÐÔÖ×Áö£¬£¬£¬£¬£¬ £¬£¬ÆäÖиÎϸ°û°©Õ¼80-85%[1]¡£¡£¡£¡£¡£¡£¡£ÖйúÊǸΰ©¸ß·¢µØÇø£¬£¬£¬£¬£¬ £¬£¬2020ÄêÖйúз¢²¡Àý41Íò£¬£¬£¬£¬£¬ £¬£¬Õ¼È«Çòз¢²¡ÀýµÄ45%£¬£¬£¬£¬£¬ £¬£¬éæÃü²¡Àý´ï39Íò£¬£¬£¬£¬£¬ £¬£¬Õ¼È«ÇòéæÃü²¡ÀýµÄ47%¡£¡£¡£¡£¡£¡£¡£ÔÚÖйú£¬£¬£¬£¬£¬ £¬£¬Ô¼70%µÄ¸Îϸ°û°©»¼Õß³õÕïʱ¼´ÎªÖÐÍíÆÚ[2]¡£¡£¡£¡£¡£¡£¡£¼ÈÍùÕë¶ÔÍíÆÚ¸Îϸ°û°©µÄÖÎÁÆÑ¡ÔñÓÐÏÞ£¬£¬£¬£¬£¬ £¬£¬µ«Ëæ×ÅÃâÒßÖÎÁƵÄÍƹ㣬£¬£¬£¬£¬ £¬£¬ÃâÒßÍŽΌѪ¹ÜÌìÉúÖÎÁÆÖð²½³ÉΪһÏßϵͳÖÎÁƵÄÐÂÑ¡Ôñ¡£¡£¡£¡£¡£¡£¡£
°²ÂÞÌæÄáÒ»ÏßÖÎÁÆÍíÆÚ¸Îϸ°û°©µÄÉÏÊÐÉêÇë»ñÊÜÀí£¬£¬£¬£¬£¬ £¬£¬Ö÷ÒªÊÇ»ùÓÚÒ»Ïî¢óÆÚÁÙ´²Ñо¿£¨ALTN-AK105-¢ó-02£©ËùÈ¡µÃµÄ“Ë«ÖÕµãÑôÐÔ”Æð¾¢Ð§¹û¡£¡£¡£¡£¡£¡£¡£¸ÃÑо¿ÊÇÒ»Ïî¶àÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å¡¢Æ½ÐбÈÕÕ¢óÆÚÁÙ´²Ñо¿£¬£¬£¬£¬£¬ £¬£¬Ö¼ÔÚÆÀ¹À°²ÂÞÌæÄáÍŽáÅÉ°²ÆÕÀûµ¥¿¹±ÈÕÕË÷À·ÇÄáÒ»ÏßÖÎÁÆÍíÆÚ¸Îϸ°û°©µÄÓÐÓÃÐÔºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£
¸ÃÑо¿¹²ÄÉÈëÍíÆڸΰ©»¼Õß649Àý¡£¡£¡£¡£¡£¡£¡£ÆäÖУ¬£¬£¬£¬£¬ £¬£¬40.9%µÄÊÜÊÔÕß°éÓдóѪ¹ÜÇÖÕ¼£¬£¬£¬£¬£¬ £¬£¬¼×Ì¥ÂÑ°×(AFP)≥400ng/mLµÄ»¼Õß±ÈÀýΪ49.2%¡£¡£¡£¡£¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬ £¬£¬ÊÔÑé×éÖÐλÎÞÏ£ÍûÉúÑÄʱ¼ä£¨PFS£©Îª6.9¸öÔ£¬£¬£¬£¬£¬ £¬£¬±ÈÕÕ×éΪ2.8¸öÔ£¬£¬£¬£¬£¬ £¬£¬¼²²¡Ï£Íû»òéæÃüΣº¦ÏÔÖø½µµÍ47% £»£»£»£»£»£»ÊÔÑé×éÖÐλ×ÜÉúÑÄÆÚ£¨OS£©Îª16.5¸öÔ£¬£¬£¬£¬£¬ £¬£¬±ÈÕÕ×éΪ13.2¸öÔ£¬£¬£¬£¬£¬ £¬£¬éæÃüΣº¦ÏÔÖø½µµÍ31%[3]¡£¡£¡£¡£¡£¡£¡£»ùÓÚ´Ë£¬£¬£¬£¬£¬ £¬£¬×ÔÁ¦Êý¾Ý¼à²éίԱ»á£¨IDMC£©ÅжÏÖ÷ÒªÑо¿ÖÕµãPFSÒÔ¼°OS¾ùµÖ´ï¼Æ»®Ô¤ÉèµÄÓÅЧ½çÖµ¡£¡£¡£¡£¡£¡£¡£
×èÖ¹ÏÖÔÚ£¬£¬£¬£¬£¬ £¬£¬ÑÎËá°²ÂÞÌæÄὺÄÒÒÑÔÚº£ÄÚÀֳɻñÅú6¸ö˳Ӧ֢£¬£¬£¬£¬£¬ £¬£¬°üÀ¨ÈýÏß·ÇСϸ°û·Î°©¡¢Èí×éÖ¯ÈâÁö¡¢ÈýÏßСϸ°û·Î°©¡¢¼××´ÏÙËèÑù°©¡¢·Ö½âÐͼ××´ÏÙ°©¡¢Ò»ÏßÆÕ±éÆÚСϸ°û·Î°©¡£¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬ £¬£¬×Ó¹¬ÄÚĤ°©¡¢Ò»ÏßÍíÆÚÉöϸ°û°©¡¢Ò»ÏßÍíÆÚÈí×éÖ¯ÈâÁöÒÔ¼°Ò»ÏßÍíÆÚ¸Îϸ°û°©Ë³Ó¦Ö¢µÄÉÏÊÐÉêÇëÏà¼Ì»ñµÃÊÜÀí£¬£¬£¬£¬£¬ £¬£¬ÓÐÍûΪ¸ü¶àÖ×Áö»¼ÕßÌṩ¶àÔª»¯¡¢¾«×¼»¯µÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
[1] Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer Statistics, 2021.CA Cancer J Clin 2021,71(1):7-33.
[2] Öйúҽʦлá¸Î°©×¨ÒµÎ¯Ô±»á.¸Îϸ°û°©È«³ÌÖÎÀíÖйúר¼Ò¹²Ê¶(2023°æ)[J].ÖлªÏû»¯Íâ¿ÆÔÓÖ¾,2023,22(7):824-842.
[3] Jian Z,et al.Primary results from the phase ¢ó ALTN-AK105-¢ó-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma(aHCC).2024 ESMO,LBA 40.
ÉùÃ÷£º
1.±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬£¬£¬ £¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬£¬£¬ £¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬£¬£¬ £¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬£¬£¬ £¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬£¬ £¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬ £¬£¬°üÀ¨Óйء¾ÑÎËá°²ÂÞÌæÄὺÄÒ¡¢ÅÉ°²ÆÕÀûµ¥¿¹×¢ÉäÒº¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬£¬£¬ £¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬ £¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬£¬£¬£¬£¬ £¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬£¬£¬£¬£¬ £¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬£¬£¬£¬£¬ £¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬ £¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬£¬ £¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£¡£¡£